Ignite Creation Date:
2025-12-25 @ 3:32 AM
Ignite Modification Date:
2026-05-09 @ 6:06 PM
Study NCT ID:
NCT00168805
Status:
COMPLETED
Last Update Posted:
2014-05-19
First Post:
2005-09-12
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery
Sponsor:
Boehringer Ingelheim
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
1160.25
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Boehringer Ingelheim, Study Chair
Old Organization:
Boehringer Ingelheim